AC-262536 vs Ostarine

AC-262536 wins for: Minimal androgenic side effects (hair/skin safe), milder HPTA suppression at effective doses, friendlier for multi-cycle users and bridging between heavier runs. Great for users prioritizing low side-effect load and partial-agonist safety net.

Ostarine wins for: Clinically validated lean-mass retention, more robust anabolic effect per mg, established dosing protocols, and reliable results in both men and women. Standard pick for first cycles, recomp, and contest prep. Slightly more potent and better studied. Sourcing is generally easier.

Pick AC-262536 if:

• You want a gentle SARM for your first run and are nervous about hair, skin, or prostate sides.
• You need a bridge or cruise between more suppressive cycles, but still want a noticeable anabolic edge.
• You already stacked harsher compounds and want to minimize cumulative HPTA shutdown.
• You're stacking with hair-preservation agents (finasteride, RU58841) and want to avoid DHT-like pressure.
• Side effect minimization is the priority — even at the cost of some potency.

Pick Ostarine if:

• You want the most time-tested, predictable SARM for lean mass retention, especially in a caloric deficit.
• Potency-per-milligram matters and mild suppression is acceptable.
• You're running a cut or recomp as a male or female user and want clear data-backed results.
• Reliable sourcing and broad anecdotal history matter to you (vs. the research-only/gray market for AC-262536).
• You value higher ceiling on lean-mass gains than what partial-agonist SARMs offer.